Corcept Shares Rise More Than 60% in Three Months: Here's Why

19 hours ago · Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry ’s decline of 9.9%. The company’s sole-marketed drug, …

CouponFollow Extension

60%
OFF

Corcept Shares Rise More Than 60% In Three Months: Here's Why

6 days from now

19 hours ago · Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry ’s decline of 9.9%. The company’s sole-marketed drug, …

nasdaq.com

60%
OFF

Corcept Shares Rise More Than 60% In Three Months: Here's Why

6 days from now

17 hours ago · Spero Therapeutics Inc. Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%.The company’s …

barchart.com

45%
OFF

Corcept Shares Rise More Than 45% In Six Months: Here's Why

6 days from now

Shares of Corcept Therapeutics Incorporated CORT have gained 46.2% in the past six months against the industry’s decline of 2%. The company’s sole-marketed drug, Korlym …

msn.com

45%
OFF

Corcept Shares Rise More Than 45% In Six Months: Here's Why

6 days from now

Sep 3, 2024 · Corcept currently carries a Zacks Rank #3 (Hold). FULC - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s …

zacks.com

20%
OFF

Corcept (CORT) Up More Than 20% In Past 3 Months: Here's Why

6 days from now

Sep 14, 2022 · MRK. Shares of Corcept Therapeutics Incorporated CORT have rallied 22.1% in the past three months compared with the industry’s rise of 6.9%. Corcept’s only marketed …

yahoo.com

50%
OFF

Corcept (CORT) Up More Than 50% In Past 3 Months: Here's Why

6 days from now

Dec 31, 2020 · Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

yahoo.com

45%
OFF

Corcept Shares Rise More Than 45% In Six Months: Here's Why

6 days from now

Sep 3, 2024 · In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from …

nasdaq.com

20%
OFF

Corcept (CORT) Shares Rise 20% In Three Months: Here's Why

6 days from now

Jun 26, 2024 · Shares of Corcept Therapeutics Incorporated (. CORT Quick Quote. CORT - Free Report) have rallied 20% in the past three months against the industry ’s decline of 4.9%. The …

zacks.com

45%
OFF

Corcept Therapeutics (NASDAQ:CORT) Stock Quotes, Forecast

6 days from now

Nov 1, 2024 · Corcept Shares Rise More Than 45% in Six Months: Here's Why. Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) have gained 46.2% in the past six …

benzinga.com

20%
OFF

Corcept (CORT) Shares Rise 20% In Three Months: Here's Why

6 days from now

Jun 26, 2024 · Shares of Corcept Therapeutics Incorporated CORT have rallied 20% in the past three months against the industry’s decline of 4.9%.. The company has made steady progress …

yahoo.com

69%
OFF

Corcept Therapeutics (CORT) Stock Price, News & Analysis

6 days from now

4 days ago · Earnings Growth39.69%. Earnings for Corcept Therapeutics are expected to grow by 39.69% in the coming year, from $1.31 to $1.83 per share. The P/E ratio of Corcept …

marketbeat.com

45%
OFF

Corcept Shares Rise More Than 45% In Six Months: Here's Why

6 days from now

Sep 3, 2024 · Shares of Corcept Therapeutics Incorporated CORT have gained 46.2% in the past six months against the industry’s decline of 2%. The company’s sole-marketed drug, Korlym …

tradingview.com

$0.91
OFF

3 Reasons Growth Investors Will Love Corcept (CORT)

6 days from now

2 days ago · Right now, Corcept has an S/TA ratio of 0.91, which means that the company gets $0.91 in sales for each dollar in assets. Comparing this to the industry average of 0.42, it can …

zacks.com

20%
OFF

Corcept (CORT) Shares Rise 20% In Three Months: Here's Why

6 days from now

Jun 26, 2024 · Shares of Corcept Therapeutics Incorporated CORT have rallied 20% in the past three months against the industry’s decline of 4.9%.. The company has made steady progress …

tradingview.com

6%
OFF

Why Corcept Therapeutics Stock Was Up 11.6% Friday

6 days from now

Dec 10, 2021 · Corcept Therapeutics (CORT 9.76%) shares, which closed at $17.10 a share on Thursday, rose 11.6% on Friday. The stock opened at $17.52, then climbed to as high as …

fool.com

FAQs about Corcept Shares Rise More Than 60% in Three Months: Here's Why Coupon?

Is Corcept Therapeutics Inc (Cort) a good stock to buy?

Shares of Corcept Therapeutics Incorporated CORT have gained 46.2% in the past six months against the industry’s decline of 2%. The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters. ...

Is Corcept Therapeutics a profitable MidCap biotechnology company?

Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas. Recent study... Corcept Therapeutics' strong Q2 earnings exceed expectations, with revenue climbing 39% YoY and EPS beating analyst estimates. ...

Will Korlym relacorilant push Corcept stock up in 2024?

The strong demand for Korlym is likely to continue the momentum for Corcept. Also, a potential approval for relacorilant should help Corcept address a broader patient population, which should push the stock upward later in 2024. Corcept Therapeutics Incorporated price | Corcept Therapeutics Incorporated Quote ...

Is Corcept Therapeutics Inc (CRT) stock undervalued?

Currently, the GF Value of Corcept Therapeutics Inc is $29.91, indicating that the stock is fairly valued. However, three months ago, the GF Value was $27.33, suggesting that the stock was modestly undervalued at that time. Warning! ...

How many research reports have been made about Corcept Therapeutics?

In the past 90 days, only 3 research reports have been made about Corcept Therapeutics. Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company that engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. ...

What are the 1 year price objectives for Corcept Therapeutics' stock?

According to 4 Wall Street research analysts, the predicted 1 year price objectives for Corcept Therapeutics' stock range from $22.00 to $32.00. The average forecast is for the company's stock price to reach $28.50 in the next twelve months, suggesting a possible upside of 35.0% from the current price. ...